TDC
OCUL icon

Thompson Davis & Co’s Ocular Therapeutix OCUL Stock Holding History

Thompson Davis & Co’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-125
Closed -$1K – 1210
2016
Q4 		$1K Hold
125
– – ﹤0.01% 1090
2016
Q3 		$1K Hold
125
– – ﹤0.01% 1069
2016
Q2 		$1K Hold
125
– – ﹤0.01% 1020
2016
Q1 		$1K Hold
125
– – ﹤0.01% 1030
2015
Q4 		$1K Hold
125
– – ﹤0.01% 1091
2015
Q3 		$2K Hold
125
– – ﹤0.01% 1027
2015
Q2 		$3K Hold
125
– – ﹤0.01% 1020
2015
Q1 		$5K Sell
125
-250
-67% -$8.22K 0.01% 902
2014
Q4 		$9K Buy
375
+125
+50% +$2.1K 0.01% 776
2014
Q3 		$4K Buy
+250
New +$3.7K 0.01% 947

Other funds holding OCUL

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Thompson Davis & Co's OCUL Position: Q1 2017 in Review

Thompson Davis & Co sold out of Ocular Therapeutix (OCUL) in Q1 2017, closing a stake of 125 shares — an estimated $1K sold.

Thompson Davis & Co first reported a position in OCUL in Q3 2014 and held it in 10 quarters. The position peaked at $9K in Q4 2014. 73 funds tracked by Wall St. Rank hold OCUL as of Q1 2017.

  • Thompson Davis & Co reported no remaining Ocular Therapeutix position as of Q1 2017 after selling out during the quarter.
  • Thompson Davis & Co sold 125 Ocular Therapeutix shares in Q1 2017, an estimated $1K.
  • Thompson Davis & Co first reported a position in Ocular Therapeutix in Q3 2014 and held it in 10 quarters.
  • Thompson Davis & Co's Ocular Therapeutix position peaked at $9K in Q4 2014.
  • 73 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2017.

Based on Thompson Davis & Co's 13F filing for Q1 2017, filed 8 May 2017.